Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $6.1 million.

  • United Therapeutics' Other Non Operating Income rose 517.24% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$900000.0, marking a year-over-year decrease of 11153.85%. This contributed to the annual value of $5.8 million for FY2024, which is 14142.86% up from last year.
  • Latest data reveals that United Therapeutics reported Other Non Operating Income of $6.1 million as of Q3 2025, which was up 517.24% from -$100000.0 recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' Other Non Operating Income peaked at $97.2 million during Q1 2021, and registered a low of -$51.8 million during Q2 2022.
  • Over the past 5 years, United Therapeutics' median Other Non Operating Income value was -$2.6 million (recorded in 2024), while the average stood at -$236842.1.
  • Over the last 5 years, United Therapeutics' Other Non Operating Income had its largest YoY gain of 101724.14% in 2021, and its largest YoY loss of 2340000.0% in 2021.
  • Quarter analysis of 5 years shows United Therapeutics' Other Non Operating Income stood at -$28.8 million in 2021, then skyrocketed by 81.6% to -$5.3 million in 2022, then surged by 88.68% to -$600000.0 in 2023, then crashed by 333.33% to -$2.6 million in 2024, then surged by 334.62% to $6.1 million in 2025.
  • Its Other Non Operating Income stands at $6.1 million for Q3 2025, versus -$100000.0 for Q2 2025 and -$4.3 million for Q1 2025.